National Eye Institute; Notice of Closed Meeting, 28851 [2021-11294]
Download as PDF
<![CDATA[
Federal Register / Vol. 86, No. 102 / Friday, May 28, 2021 / Notices
Dated: May 24, 2021.
Lauren K. Roth,
Acting Principal Associate Commissioner for
Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2021–11384 Filed 5–27–21; 8:45 am]
National Eye Institute; Notice of Closed
Meeting
BILLING CODE 4164–01–C
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Eye Institute; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Eye Institute
Special Emphasis Panel; NEI Clinical Trials
and Clinical Applications I.
Date: June 24, 2021.
Time: 11:00 a.m. to 2:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Eye Institute, National
Institutes of Health, 6700B Rockledge Drive,
Suite 3400, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Jennifer C Schiltz, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Activities,
National Eye Institute, National Institutes of
Health, 6700B Rockledge Drive, Suite 3400,
Bethesda, MD 20817, 240–276–5864,
jennifer.schiltz@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.867, Vision Research,
National Institutes of Health, HHS)
Dated: May 24, 2021.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–11294 Filed 5–27–21; 8:45 am]
BILLING CODE 4140–01–P
National Institutes of Health
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Eye Institute
Special Emphasis Panel; NEI Clinical Trials
and Clinical Applications II.
Date: June 28, 2021.
Time: 10:00 a.m. to 2:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Eye Institute, National
Institutes of Health, 6700B Rockledge Drive,
Suite 3400, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Jennifer C. Schiltz, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Activities,
National Eye Institute, National Institutes of
Health, 6700B Rockledge Drive, Suite 3400,
Bethesda, MD 20817, 240–276–5864,
jennifer.schiltz@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.867, Vision Research,
National Institutes of Health, HHS)
Dated: May 24, 2021.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–11293 Filed 5–27–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
Federal Emergency Management
Agency
[Docket ID FEMA–2020–0016]
Pandemic Response Voluntary
Agreement Under Section 708 of the
Defense Production Act; Plans of
Action To Respond to COVID–19
Federal Emergency
Management Agency, Department of
Homeland Security.
ACTION: Notice.
AGENCY:
VerDate Sep<11>2014
17:28 May 27, 2021
Jkt 253001
PO 00000
Frm 00105
Fmt 4703
Sfmt 4703
28851
The Federal Emergency
Management Agency (FEMA)
announces the formation of four Plans
of Action under the Voluntary
Agreement for the Manufacture and
Distribution of Critical Healthcare
Resources Necessary to Respond to a
Pandemic: Plan of Action to Establish a
National Strategy for the Manufacture,
Allocation, and Distribution of
Diagnostic Test Kits and other Testing
Components to Respond to COVID–19;
Plan of Action to Establish a National
Strategy for the Manufacture,
Allocation, and Distribution of Drug
Products, Drug Substances, and
Associated Medical Devices to Respond
to COVID–19; Plan of Action to
Establish a National Strategy for the
Manufacture, Allocation, and
Distribution of Medical Devices to
Respond to COVID–19; and Plan of
Action to Establish a National Strategy
for the Manufacture, Allocation, and
Distribution of Medical Gases to
Respond to COVID–19. This notice
contains the text of all four Plans of
Action.
SUMMARY:
FOR FURTHER INFORMATION CONTACT:
Robert Glenn, Office of Business,
Industry, Infrastructure Integration, via
email at OB3I@fema.dhs.gov or via
phone at (202) 212–1666.
SUPPLEMENTARY INFORMATION:
Background and Legal Authority
The Defense Production Act (DPA), 50
U.S.C. 4501 et seq., authorizes the
making of ‘‘voluntary agreements and
plans of action’’ with, among others,
representatives of industry and business
to help provide for the national
defense.1 The President’s authority to
facilitate voluntary agreements was
delegated to the Secretary of Homeland
Security with respect to responding to
the spread of COVID–19 within the
United States in Executive Order
13911.2 The Secretary of Homeland
Security has further delegated this
authority to the FEMA Administrator.3
On August 17, 2020, after the
appropriate consultations with the
Attorney General and the Chairman of
the Federal Trade Commission and after
requesting and considering public
comments, FEMA completed and
published in the Federal Register a
‘‘Voluntary Agreement, Manufacture
and Distribution of Critical Healthcare
Resources Necessary to Respond to a
1 50
U.S.C. 4558(c)(1).
FR 18403 (Apr. 1, 2020).
3 DHS Delegation 09052, Rev. 00.1 (Apr. 1, 2020);
DHS Delegation Number 09052 Rev. 00 (Jan. 3,
2017).
2 85
E:\FR\FM\28MYN1.SGM
28MYN1
]]>Agencies
[Federal Register Volume 86, Number 102 (Friday, May 28, 2021)]
[Notices]
[Page 28851]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-11294]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Eye Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Eye Institute Special Emphasis
Panel; NEI Clinical Trials and Clinical Applications I.
Date: June 24, 2021.
Time: 11:00 a.m. to 2:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Eye Institute, National Institutes of Health,
6700B Rockledge Drive, Suite 3400, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Jennifer C Schiltz, Ph.D., Scientific Review
Officer, Scientific Review Branch, Division of Extramural
Activities, National Eye Institute, National Institutes of Health,
6700B Rockledge Drive, Suite 3400, Bethesda, MD 20817, 240-276-5864,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.867,
Vision Research, National Institutes of Health, HHS)
Dated: May 24, 2021.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-11294 Filed 5-27-21; 8:45 am]
BILLING CODE 4140-01-P
